News and publications
Promethera Biosciences presented at the ISCT Annual Meeting in Paris and recorded a podcast on Cell Therapy Commercialization
Mont-Saint-Guibert, Belgium - April 26, 2014 – Promethera Biosciences actively participated at the 21th International Society Cellular Therapy (ISCT) Annual Congress which took place in Paris (France) in April, 23-26, 2014. On Saturday, the 26th, Promethera Biosciences was speaker at the session “Strategies for Commercialization: Building a Globally Successful Cell Therapy Product”.
ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients’ lives. ISCT Members gain access to an influential global community of peers, experts, and organizations invested in cell therapy. ISCT offers a unique collaboration between academia, regulatory bodies, and industry partners in cell therapy translation.
The Pre-Event Podcast Series has offered with a unique preview on Cell Therapy Commercialization. To this end, Eric Halioua, CEO and co-founder of Promethera Biosciences, was recorded when speaking about HepaStem, a cell-based therapy for liver diseases currently in clinical trials. Eric Halioua highlighted the challenges that Promethera has faced in producing HepaStem to make the product viable, as well as the company's unique answer to logistical and regulatory challenges in Europe (patent pending): A GMP van. The company has also developed a prefilled syringe and vial that allows for reconstitution of the cell therapy product that they will be using for their next phase of clinical trials. This podcast was originally recorded by BioProcess International.
PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01